Literature DB >> 14635722

MCASE study of the multidrug resistance reversal activity of propafenone analogs.

Gilles Klopman1, Hao Zhu, Gerhard Ecker, Peter Chiba.   

Abstract

A database containing 130 propafenone type chemicals which have been tested for their multidrug resistance (MDR) reversal activity was compiled. Using the Multiple Computer-Automated Structure Evaluation (MCASE) program to analyze this database, an underlying relationship between MDR reversal activity and octanol/water partition coefficient was found. An MDR reversal model was created based on this database by the baseline activity identification algorithm (BAIA) of the MCASE program. The main phamacophores relevant to MDR reversal activity were identified.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14635722     DOI： 10.1023/a:1026124505322

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN： 0920-654X            Impact factor:   3.686


  20 in total

Review 1.  Structure-activity relationships of multidrug resistance reversers.

Authors:  M Wiese; I K Pajeva
Journal:  Curr Med Chem       Date:  2001-05       Impact factor: 4.530

2.  Synthesis and in vitro multidrug resistance modulating activity of a series of dihydrobenzopyrans and tetrahydroquinolines.

Authors:  R Hiessböck; C Wolf; E Richter; M Hitzler; P Chiba; M Kratzel; G Ecker
Journal:  J Med Chem       Date:  1999-06-03       Impact factor: 7.446

3.  Determination of the new MDR-modifier PFP 6 and its metabolites in human liver microsomes by high-performance liquid chromatography.

Authors:  M Spatzenegger; G Ecker; W Jäger
Journal:  Biomed Chromatogr       Date:  1996 May-Jun       Impact factor: 1.902

4.  The MultiCASE program II. Baseline activity identification algorithm (BAIA).

Authors:  G Klopman
Journal:  J Chem Inf Comput Sci       Date:  1998 Jan-Feb

5.  Studies on propafenone-type modulators of multidrug-resistance IV1): synthesis and pharmacological activity of 5-hydroxy and 5-benzyloxy derivatives.

Authors:  P Chiba; B Tell; W Jäger; E Richter; M Hitzler; G Ecker
Journal:  Arch Pharm (Weinheim)       Date:  1997-11       Impact factor: 3.751

6.  Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance.

Authors:  J M Ford; W C Prozialeck; W N Hait
Journal:  Mol Pharmacol       Date:  1989-01       Impact factor: 4.436

7.  Structure-activity relationship studies on benzofuran analogs of propafenone-type modulators of tumor cell multidrug resistance.

Authors:  G Ecker; P Chiba; M Hitzler; D Schmid; K Visser; H P Cordes; J Csöllei; J K Seydel; K J Schaper
Journal:  J Med Chem       Date:  1996-11-22       Impact factor: 7.446

8.  [Synthesis and pharmacodynamic activity of 2-(3-(2-phenylethyl)benzofuran-2-yl)-N-propyl-ethanamine].

Authors:  G Ecker; T Helml; W Fleischhacker; C R Noe; C Studenik; B Schade; P Heistracher
Journal:  Arch Pharm (Weinheim)       Date:  1995-04       Impact factor: 3.751

9.  Substituted 4-acylpyrazoles and 4-acylpyrazolones: synthesis and multidrug resistance-modulating activity.

Authors:  P Chiba; W Holzer; M Landau; G Bechmann; K Lorenz; B Plagens; M Hitzler; E Richter; G Ecker
Journal:  J Med Chem       Date:  1998-10-08       Impact factor: 7.446

10.  Synthesis, pharmacologic activity, and structure-activity relationships of a series of propafenone-related modulators of multidrug resistance.

Authors:  P Chiba; S Burghofer; E Richter; B Tell; A Moser; G Ecker
Journal:  J Med Chem       Date:  1995-07-07       Impact factor: 7.446
View more
  2 in total

Review 1.  From QSAR to QSIIR: searching for enhanced computational toxicology models.

Authors:  Hao Zhu
Journal:  Methods Mol Biol       Date:  2013

2.  Use of cell viability assay data improves the prediction accuracy of conventional quantitative structure-activity relationship models of animal carcinogenicity.

Authors:  Hao Zhu; Ivan Rusyn; Ann Richard; Alexander Tropsha
Journal:  Environ Health Perspect       Date:  2008-04       Impact factor: 9.031
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.